ERBB2 and breast carcinoma: This absence of hormone receptors and HER2 makes TNBC distinct from other breast cancer subtypes, as it does not respond to hormonal therapy or therapies that target HER2 receptors, resulting in limited treatment options and a generally poorer prognosis [1].